Barinthus Biotherapeutics plc.
About Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$66.4M
- Total assets
- $98.2M
- Market cap
- $26.6M
- Operating margin
- -13943.7%
- Net margin
- -13134.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $506.0K
- Operating expenses
- $71.1M
- Operating income
- -$70.6M
- Income tax
- -$175.0K
- Net income
- -$66.5M
- EPS (basic)
- $-1.64
- EPS (diluted)
- $-1.64
Balance sheet
- Total assets
- $98.2M
- Current assets
- $77.8M
- Total liabilities
- $23.9M
- Current liabilities
- $10.0M
- Shareholders’ equity
- $74.3M
Cash flow
- Operating cash flow
- -$48.0M
- Investing cash flow
- $416.0K
- Financing cash flow
- $2.0K
- Net cash flow
- -$47.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $26.6M
- EPS (diluted)
- $-1.64
- Shares outstanding
- 38.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 30, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $66.4M in FY2025.
- Revenue declined 37% from FY2023 to FY2025.
- Trading 65% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Barinthus Biotherapeutics plc..
Write a review
News about Barinthus Biotherapeutics plc.
News & sentiment via Polygon.io
